Literature DB >> 19734428

Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia.

Esther Hulleman, Mathilde J C Broekhuis, Rob Pieters, Monique L Den Boer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19734428      PMCID： PMC2738730          DOI： 10.3324/haematol.2009.011437

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

Review 1.  Pyruvate kinase type M2 and its role in tumor growth and spreading.

Authors:  Sybille Mazurek; C Bruce Boschek; Ferdinand Hugo; Erich Eigenbrodt
Journal:  Semin Cancer Biol       Date:  2005-08       Impact factor: 15.707

Review 2.  Treatment of acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  N Engl J Med       Date:  2006-01-12       Impact factor: 91.245

Review 3.  Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia.

Authors:  R Pieters; E Klumper; G J Kaspers; A J Veerman
Journal:  Crit Rev Oncol Hematol       Date:  1997-01       Impact factor: 6.312

Review 4.  Cancer's molecular sweet tooth and the Warburg effect.

Authors:  Jung-whan Kim; Chi V Dang
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

5.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions.

Authors:  R Pieters; A H Loonen; D R Huismans; G J Broekema; M W Dirven; M W Heyenbrok; K Hählen; A J Veerman
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

6.  The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.

Authors:  K Koss; R F Harrison; J Gregory; S J Darnton; M R Anderson; J A Z Jankowski
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

7.  Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.

Authors:  M L Den Boer; D O Harms; R Pieters; K M Kazemier; U Gobel; D Körholz; U Graubner; R J Haas; N Jorch; H J Spaar; G J L Kaspers; W A Kamps; A Van der Does-Van den Berg; E R Van Wering; A J P Veerman; G E Janka-Schaub
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

8.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

9.  Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.

Authors:  Esther Hulleman; Karin M Kazemier; Amy Holleman; David J VanderWeele; Charles M Rudin; Mathilde J C Broekhuis; William E Evans; Rob Pieters; Monique L Den Boer
Journal:  Blood       Date:  2008-10-31       Impact factor: 22.113

10.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.

Authors:  G J Kaspers; R Pieters; C H Van Zantwijk; E R Van Wering; A Van Der Does-Van Den Berg; A J Veerman
Journal:  Blood       Date:  1998-07-01       Impact factor: 22.113
View more
  5 in total

1.  An integrated approach to elucidate signaling pathways of dioscin-induced apoptosis, energy metabolism and differentiation in acute myeloid leukemia.

Authors:  She-Hung Chan; Pi-Hui Liang; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-03-28       Impact factor: 3.000

2.  Molecular simulation of Tyr105 phosphorylated pyruvate kinase M2 to understand its structure and dynamics.

Authors:  Ponnusamy Kalaiarasan; Naidu Subbarao; Rameshwar Nk Bamezai
Journal:  J Mol Model       Date:  2014-09-11       Impact factor: 1.810

3.  In silico screening, genotyping, molecular dynamics simulation and activity studies of SNPs in pyruvate kinase M2.

Authors:  Ponnusamy Kalaiarasan; Bhupender Kumar; Rupali Chopra; Vibhor Gupta; Naidu Subbarao; Rameshwar N K Bamezai
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

4.  Pyruvate kinase is a dosage-dependent regulator of cellular amino acid homeostasis.

Authors:  Katharina Bluemlein; Matthias Glückmann; Nana-Maria Grüning; René Feichtinger; Antje Krüger; Mirjam Wamelink; Hans Lehrach; Stephen Tate; Daniel Neureiter; Barbara Kofler; Markus Ralser
Journal:  Oncotarget       Date:  2012-11

5.  Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia.

Authors:  Jing Li; Shanshan Li; Jianshuang Guo; Qiuying Li; Jing Long; Cheng Ma; Yahui Ding; Chunli Yan; Liangwei Li; Zhigang Wu; He Zhu; Keqin Kathy Li; Liuqing Wen; Quan Zhang; Qingqing Xue; Caili Zhao; Ning Liu; Ivaylo Ivanov; Ming Luo; Rimo Xi; Haibo Long; Peng George Wang; Yue Chen
Journal:  J Med Chem       Date:  2018-04-29       Impact factor: 7.446
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.